Recent imaging and postmortem studies suggest that impaired connectivity is involved in the pathophysiology of schizophrenia and major affective disorders. We investigated the presynaptic proteins complexin (Cx) I and Cx II in postmortem prefrontal cortex in schizophrenia (n = 13; six suicide, seven nonsuicide), major depression (n = 11, all suicide) and controls (n = 11) with an enzyme-linked immunoadsorbent assay (ELISA). Overall analysis indicated a significant difference between groups (F = 3.93, P = 0.007). Cx I (enriched in inhibitory terminals) was decreased 33% in schizophrenia (26% in schizophrenia/nonsuicide, 42% in schizophrenia/suicide) and 27% in major depression. Cx II (enriched in excitatory terminals) was not significantly different. Analysis of the ratio of Cx II/Cx I was carried out as an indication of the balance of excitatory to inhibitory terminals. A significant difference between groups (ANOVA, F = 6.42, P = 0.005) was observed. The mean value of Cx II/Cx I was significantly increased by 34% in schizophrenia (26% in schizophrenia/nonsuicide and 43% in schizophrenia/suicide) and by 32% in depression compared with control (Student-NewmanKeuls test, P = 0.05). Immunoreactivities of the two complexins were highly correlated in all groups. However, compared with controls and depression, samples from cases with schizophrenia appeared to have relatively less Cx I for similar amounts of Cx II. Immunocytochemical studies of rat frontal cortex after 3 weeks treatment with chlorpromazine, trifluoperazine or haloperidol revealed no differences in complexins, synaptophysin, SNAP-25, syntaxin or VAMP in comparison with animals treated with vehicle. Alterations of complexins may contribute to the molecular substrate for abnormalities of neural connectivity in severe mental disorders.
Introduction
Imaging and postmortem studies reveal evidence of macro-and microscopic alterations of brain structure in schizophrenia and in depression. [1] [2] [3] Complementary functional brain imaging studies indicate impaired connectivity between the frontal lobe and other brain regions in both disorders. 4 At the cellular and molecular level, postmortem histopathologic studies of the frontal lobe in schizophrenia demonstrated reduced neuronal size, 5 decreased density of dendritic spines, 6, 7 and altered synaptic protein immunoreactivity or mRNA levels. [8] [9] [10] [11] These observations suggest that abnormal synaptic connectivities are involved in the pathophysiology of schizophrenia and other neuropsychiatric disorders. 12 Complexin (Cx) I and Cx II were initially identified as presynaptic proteins capable of interacting with the SNARE complex, which is the molecular substrate for vesicular fusion to the presynaptic membrane. [13] [14] [15] Although Cx I and Cx II are highly homologous proteins, their distribution differs. An initial study with electron microscopy in mouse demonstrated axodendritic terminals (including axospinal types) were enriched for Cx II, while axosomatic terminals were enriched for Cx I.
14 Subsequent studies in rat cortex indicated a similar pattern of association between terminal ultrastructure and complexin type. 16 A study of cultured neurons showed many cells were immunoreactive for both complexins, however individual terminals were largely (but not exclusively) immunostained for one type of complexin alone. 17 Based on the distribution profile of terminals, Cx I was suggested to be predominantly expressed in GABAergic, inhibitory interneurons, and Cx II predominantly expressed in glutamatergic, excitatory pyramidal neurons. 18 In the hippocampal formation in schizophrenia, a decreased ratio of Cx II/Cx I protein and Cx II/Cx I mRNA was interpreted as implying preferential involvement of hippocampal excitatory connections in the pathophysiology of schizophrenia. 18 A subsequent study did not replicate the disturbance in the Cx II/Cx I ratio, however Cx I and Cx II mRNA expression was decreased in schizophrenia and in bipolar disorder. 19 The present study sought to determine if Cx I or Cx II were altered in prefrontal cortex in schizophrenia, and in major depression with suicide. The possible effects of antipsychotic drugs on the immunoreactivities of Cx I and Cx II in frontal cortex were studied in rats administered haloperidol, trifluoperazine or chlorpromazine.
Materials and methods

Subjects and controls
Frozen samples of anterior frontal cortex (anterolateral inferior or middle frontal gyrus, approximating BA9/10) were available from 13 cases of schizophrenia, 11 cases of major depression and 11 controls (see Table  1 ). These samples were used in previous studies of synaptophysin and of SNARE protein interactions. 11, 20 All cases with depression and six cases with schizophrenia (sch/sui) died of suicide, most other cases died suddenly of causes such as homicide or myocardial infarction. Following chart review by a research psychiatrist, diagnoses were made according to DSM-III-R criteria, or for some earlier cases of schizophrenia, the Diagnostic Evaluation After Death (Feighner criteria) was used. The DSM-III-R and Feighner criteria are largely consistent for the diagnosis of schizophrenia.
ELISA
Monoclonal antibodies reactive with Cx I (SP33, 1:10) and Cx II (LP27, 1:10) were used to quantify antigen immunoreactivity with an ELISA. 21 In brief, homogenates of gray matter were prepared using Tris-buffered saline (TBS: 10 mM Tris-HCl, 140 mM NaCl, pH 7.4) prior to determination of protein concentration, and dilution to a concentration of 60 g ml −1 with distilled water. Following seven additional steps of 1:1 serial dilution (128-fold), duplicate samples at each dilution were dried onto individual wells of a 96-well plate. Incubation in 5% non-fat milk in Tris buffered saline (TBS) for 1 h at room temperature was used to inhibit non-specific binding. Primary monoclonal antibodies (diluted 1:10 in 5% non-fat milk in TBS, 50 l) were applied to each well and incubated overnight at 4°C. Plates were washed five times with 0.02% Tween-TBS, and peroxidase-conjugated secondary antibody (Jackson Immunolabs, 1:1000 in 5% milk-TBS) was applied for 1 h at room temperature. Following five additional washes, 50 l of 2,2Ј-azino-di-3-ethylbenzthiazoline sulphonate (Bio-Rad, Hercules, CA, Molecular Psychiatry USA) were added to each well and incubated for 30 min. The optical density (OD) was then determined at 405 nm. Supernatant from the parental, non-secreting myeloma cell line was used to determine background reactivity, and the OD values from the blanks were subtracted from the OD values from each sample. To compare immunoreactivity between homogenate samples, the sum of the optical density readings for an 8-fold linear range (first four steps) in duplicate was used. Samples were assayed blind to diagnosis. Samples were run twice, on different days, and the mean values used for analyses. The R values of run-to-run correlations were 0.85 for Cx I and 0.80 for Cx II.
Immunoblot study
Immunoblotting was used to confirm the antibodies were detecting bands of the expected molecular weight. 21 Each lane of a 12% polyacrylamide gel was loaded with 25 g of control or schizophrenia brain homogenate. Following electrophoresis and transfer, primary antibodies SP33 and LP27 (1:10) were applied overnight at 4°C. An immunoperoxidase detection technique was used.
Animals and drug administration
Twenty-two adult male Sprague-Dawley rats (250-275 g; Animal Care Center, University of British Columbia, Vancouver, Canada) were housed individually in hanging wire cages (24 × 16 × 40 cm). All animals were maintained on a 12 h light-dark cycle (lights on 7 am-7 pm). The colony room temperature was maintained at 20°C (±1°C) and rats had unlimited access to food (Purina Rat Chow) and water. Animals were randomly divided into four groups. Separate groups received a single daily i.p. injection for 21 days of one of three different anti-psychotic drugs (haloperidol (1 mg kg
) n = 6; chlorpromazine (10 mg kg
) n = 6; trifluoperazine (7 mg kg −1 ) n = 5). Chlorpromazine and trifluoperazine were dissolved in distilled water, while haloperidol was dissolved in 0.3% tartaric acid; all drugs were dissolved in a volume of 1 ml kg
The control group (n = 5) received injections of 0.3% tartaric acid vehicle only. After completion of the drug regimen, all animals were anaesthetised deeply with chloral hydrate and transcardially perfused with 200 ml of phosphate-buffered saline and 200 ml of formalin (4%). Brains were removed and stored in formalin for 48 h, then transferred into 0.05% sodium azide in trisbuffered saline until ready for analysis. All experimental procedures were conducted in accordance with the guidelines provided by the Canadian Council on Animal Care and the University of British Columbia Animal Care Committee.
Immunohistochemistry
A biological standard was used to investigate the relationship between amount of antigen present and observed optical density after immunocytochemistry. Briefly, bovine synaptosomes were prepared 22 and added to an equal volume of melted, 12% activatedbactoagar and thoroughly mixed by sonication. The antigen-bactoagar matrix was allowed to gel at room temperature, then cooled and cut into a cube. A series of cubes made with seven stepwise 1:1 dilutions of the antigen-agarose mix were prepared in parallel, along with a pure bactoagar cube. The cubes were then used to prepare a calibration block, which was embedded in paraffin and sectioned with a microtome, prior to immunocytochemistry with the same protocol as used for the tissue sections. Studies were performed on synaptophysin and SNAP-25, these antigens did not require heat retrieval procedures which were required for the others. For the studies of antipsychotic drug effects, rat brain tissue was dehydrated in a series of graded alcohols followed by wax embedding. Coronal sections 3 m in thickness were taken at the Bregma 4.20 mm level. 23 Following dewaxing, a heat retrieval procedure was used (Cx I, Cx II, VAMP, syntaxin). Sections were placed in sodium acetate pH 4, 95°C for 10 min. Semiquantitative immunohistochemistry was performed to assay multiple presynaptic proteins. 24 Antibodies used were SP33 (Cx I), LP27 (Cx II), SP15 (synaptophysin), SP12 (SNAP-25), SP6 (syntaxin) and SP10 (VAMP). All antibodies were used at 1:10 dilution. A Lee Chromalux HT 363 filter centered at 450 nm was used to complement the colour of the DAB reaction product. Images were captured using a Sony CCD video camera, Nikon lens and a Northern Light constant source light box. The image captured was medial frontal cortex (cingulate gyrus, Cg1 and Cg3 regions) identified according to an atlas. 23 Images were captured for left and right sides, and two sections per animal were studied. Regions were outlined using NIH image v 1.61, the mean gray scale pixel intensity was determined then converted to optical density using custom made standards. All readings were performed blind to group identity. The coefficient of variation for replicate measurements ranged from 6.8% to less than 1%.
Statistical analysis
The potentially confounding effects of age, postmortem interval and storage time on Cx I and II immunoreactivities were investigated using linear regression analysis. The Kolmogorov Smirov test was applied to Cx I and Cx II immunoreactivity results from each diagnostic group; no significant deviation from the normal distribution was demonstrated. The effect of diagnostic group (schizophrenia, depression, control) on Cx I and Cx II immunoreactivities was first investigated with a multivariate analysis of variance (MANOVA). This was followed by individual ANOVAs and the StudentNewman-Keuls post hoc test. Since all depressed patients had died from suicide, and previous studies had analysed the sch/sui group separately, 11,20 the analysis was also performed with four groups: sch/sui, sch/nonsui, depression, control. Analysis of Cx I and Cx II immunoreactivities of rat sections was performed by ANOVA, as were analyses of the other presynaptic proteins. Figure 1 Immunoblot study of human brain homogenates from schizophrenia (sch) and control (con). Immunoreactive bands were detected at the expected positions for Cx I and Cx II. The position of molecular weight markers in kilodaltons is indicated on the left.
Molecular Psychiatry
Results
Immunoblot studies
To characterize the expression of Cx protein in human brain, an immunoblot was performed with anti-Cx I and Cx II monoclonal antibodies (Figure 1 ). Immunore- Figure 2 Box plots of ELISA quantification of Cx I, Cx II and the ratio of Cx II/Cx I in prefrontal cortex. Percentiles are indicated by boxes (25, 50, 75 ) and bars (10, 90) with points outside these ranges also shown. Significant differences compared with controls are indicated, *P=0.05. con: control, dep: depression, sch/nonsui: schizophrenia/nonsuicide, sch/sui: schizophrenia/suicide. active bands with the expected molecular weights were detected. No difference in molecular weight was observed between control and schizophrenia.
ELISA studies
To examine Cx immunoreactivity in postmortem brain, an ELISA was used as the quantification method. This technique provides the advantage of quantification over a wide range of sample dilution, allowing more accuracy, and is highly correlated with results from immunoblotting studies. 21 Differences between the four groups were present for age (F = 5.13, P = 0.005), postmortem interval (F = 3.33, P = 0.03) and storage time (F = 4.41, P = 0.01). However, the correlations between Cx I and Cx II immunoreactivities and age (Cx I r = 0.12, Cx II r = 0.03), postmortem interval (Cx I r = 0.18, Cx II r = 0.17) and storage time (Cx I r = 0.05, Cx II r = 0.06) were not statistically significant. Covariates were not used in subsequent analyses.
Since Cx I and Cx II may represent different probes into synaptic function, a MANOVA was used for the initial comparison between three groups (schizophrenia, depression and control). This analysis indicated significant effects of group (Wilks' Lambda F = 3.93, P = 0.007) on Cx I and Cx II immunoreactivities. As shown in Figure 2 , ELISA revealed the mean value of Cx I immunoreactivity was decreased by 33% in schizophrenia and by 26% in depression compared with the control group (ANOVA, F = 3.82, P = 0.03). The difference in mean value from controls was statistically significant for both schizophrenia and depression (Student-Newman-Keuls test, P = 0.05). Although the mean value of Cx II in schizophrenia and depression appeared to be slightly decreased by about 9% in each group, no significant difference between groups was detected (ANOVA, F = 0.39, P = 0.68). Analysis of the ratio of Cx II/Cx I was carried out as an indication of the balance of excitatory to inhibitory presynaptic terminals, as suggested by Harrison and Eastwood. 18 The Cx II/Cx I ratio was significantly different between groups (ANOVA, F = 6.42, P = 0.005). The mean value of Cx II/Cx I was significantly increased in schizophrenia (34%) and depression (32%) compared with control (Student-NewmanKeuls test, P = 0.05).
Since all cases of depression died by suicide, a secondary analysis was carried out using four diagnostic groups (sch/sui, sch/nonsui/depression and control). Again, a significant effect of group (Wilks' Lambda F = 2.72, P = 0.02) on Cx I and Cx II immunoreactivities was detected. For Cx I immunoreactivity, the ANOVA results approached significance (F = 2.80, P = 0.06). The difference in mean value from controls was statistically significant for sch/sui (Student-NewmanKeuls test, P = 0.05). The Cx II/Cx I ratio was significantly different between groups (ANOVA, F = 4.81, P = 0.007), with each of the severe mental illness groups different from controls (Student-Newman-Keuls test, P = 0.05). To further characterize the relationships between Cx I and Cx II immunoreactivities, regression analysis was performed (Figure 3) . Overall, a highly significant relationship between Cx I and Cx II immunoreactivity was observed in all groups. The slopes and 95% confidence intervals were as follows: controls 0.707 (0.468-0.945); depression 0.570 (0.301-0.839); sch/nonsui 1.177 (0.645-1.708); sch/sui 1.268 (0.800-1.736). Compared with samples from controls and depression, samples from cases with schizophrenia had relatively less Cx I for similar amounts of Cx II.
Studies of antipsychotic drugs in rats
Studies of the calibration block indicated approximately linear relationships between concentration of presynaptic antigen and the optical density measured (see Figure 4) . To assess whether antipsychotic drugs affect synaptic protein immunoreactivity in rat prefrontal cortex, semi-quantitative immunohistochemistry was used in rats treated with haloperidol, trifluoperazine, chlorpromazine and vehicle. Representative images of Cx I and Cx II immunostaining are shown in Figure 5a and b. Relatively strong staining around neuronal somas was observed for Cx I immunoreactivity compared with Cx II (Figure 5c and d) . No significant differences were observed in immunostaining intensity of Cx I, Cx II, synaptophysin, SNAP-25, syntaxin or VAMP between control and antipsychotic medication treated animals (Figure 6a) .
Discussion
The present results demonstrated a significant elevation of the Cx II/Cx I ratio in prefrontal cortex in schizophrenia, independent of suicide as a cause of death. A similar change in Cx II/Cx I ratio was seen in major depression with suicide as a cause of death, unfortunately cases of depression with other causes of death were not available for analysis. Particularly in schizophrenia, the change in the Cx II/Cx I ratio appeared to be secondary to a relative loss of Cx I immunoreactivity.
Since Cx I is enriched in axosomatic, inhibitory terminals, these results suggest a relative loss of inhibitory control may be present in prefrontal cortex in schizophrenia. This result is consistent with reported GABAergic abnormalities in prefrontal cortex in schizophrenia, which include decreased density of small neurons, 25 up-regulation of GABAA receptor binding on pyramidal neurons, 26 and reduced parvalbumin-containing interneurons. 27 In contrast, a previous report demonstrated a decreased ratio of Cx II/Cx I in some subfields of the hippocampus in schizophrenia, suggesting preferential impairment of excitatory rather than inhibitory terminals in this brain region. 18 However, while an attempt at replication confirmed abnormalities of complexins in hippocampus in schizophrenia, preferential involvement of Cx II was not observed. 19 Connectivity between the hippocampus and prefrontal region in schizophrenia may be altered as part of a disturbance in corticolimbic circuitry. 28, 29 Compared with a large number of pathological investigations in the postmortem brain in schizophrenia, there are relatively few pathological studies of prefrontal cortex in mood disorders. 30 Studies of other structures indicate that in the hippocampus, decreased Cx I and Cx II mRNA expression in some subregions was reported in bipolar disorder, similar to the reduced expression of Cx I and Cx II in schizophrenia. 19 In contrast, no significantly altered expression was observed in major depression. In anterior cingulate cortex, Cx II was decreased in bipolar disorder and depression, but unchanged in schizophrenia. 31 In the present study, a significantly increased ratio of Cx II/Cx I was observed in the anterior frontal cortex in major depression, although the individual protein immunoreactivities were not altered significantly. The subjects with depression all died of suicide, suggesting an active phase of the illness near the time of death. The elevated ratio of Cx II/Cx I may be a shared molecular feature of schizophrenia and of the behavioural state associated with suicide in depressed patients. However, the slope of the relationship between the complexins in depression appeared to be different than in schizophrenia, perhaps indicating some differences in mechanism.
The possible effect of antipsychotic drug treatment on complexin and other presynaptic proteins was studied by administering three different antipsychotic drugs (haloperidol, chlorpromazine and trifluoperazine) to rats. No differences between treated and control rats were observed for either Cx I or Cx II immunostaining in frontal cortex. No change in the Cx II/I ratio was observed. The cases of schizophrenia in the present study were all likely to have been exposed to typical antipsychotic drugs. The present results concerning complexin protein and antipsychotic drugs in rats indicate the observations in the human samples are likely related to illness rather than treatment. Although no other studies have investigated the effects of antipsychotic drugs on complexin proteins in rats, there are two analyses of effects on mRNA. In the first study of frontoparietal cortex, Cx I mRNA was increased by olanzapine, but unaffected by chlorpromazine, haloperidol, risperidone or clozapine. 32 Complexin II mRNA was increased by chlorpromazine, but unaffected by the other drugs. Haloperidol and olanzapine decreased the Cx II/Cx I mRNA ratio. The second study examined only haloperidol, and reported a decrease in Cx I mRNA. 33 The relationship of changes in mRNA to protein immunoreactivity is uncertain. The present findings of no effects of antipsychotic drugs on synaptophysin, SNAP-25, syntaxin or VAMP in prefrontal cortex expand the range of proteins and drugs studied in this brain region. Previous reports indicated no effects of haloperidol on synaptophysin protein in rat or primate frontal cortex. 34, 35 A recent DNA array study of prefrontal cortex in schizophrenia indicated abnormalities of expression of genes coding for a group of presynaptic proteins. 10 Figure 6b presents a summary of the results of protein analyses in the present series of cases. Effects of diagnosis and suicide as a cause of death were observed for synaptophysin, SNAP-25, and complexin I. 11, 20 Also, abnormalities in the in vitro interactions between the core SNARE proteins (syntaxin, SNAP-25 and VAMP) were reported. These results emphasize the potential importance of considering families of proteins as potentially being abnormal in severe mental disorders, and the possible effects of phase or illness or other state variables as well as trait effects.
In conclusion, the present results contribute to the increasing number of studies describing abnormalities of presynaptic terminal proteins and their mRNAs in severe mental disorders. 8, 10, 11, 19, 36 The extent to which these results reflect changes in number of synaptic terminals related to altered GABAergic innervation of cortical targets, vs alterations in the machinery of exocytosis within individual terminals or subsets of terminals remains uncertain. Studies of multiple presynaptic markers with confocal microscopy may help resolve these issues in the future.
